These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 24140933)

  • 1. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
    Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
    Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
    Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
    Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
    Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
    Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
    J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma.
    Dong L; You S; Zhang Q; Osuka S; Devi NS; Kaluz S; Ferguson JH; Yang H; Chen G; Wang B; Grossniklaus HE; Van Meir EG
    Clin Cancer Res; 2019 Apr; 25(7):2206-2218. PubMed ID: 30563937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification.
    Okamoto W; Okamoto I; Arao T; Kuwata K; Hatashita E; Yamaguchi H; Sakai K; Yanagihara K; Nishio K; Nakagawa K
    Mol Cancer Ther; 2012 Jul; 11(7):1557-64. PubMed ID: 22729845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
    Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
    Yan HH; Jung KH; Son MK; Fang Z; Kim SJ; Ryu YL; Kim J; Kim MH; Hong SS
    Oncotarget; 2014 Oct; 5(19):9150-68. PubMed ID: 25193856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.
    Gangemi R; Mirisola V; Barisione G; Fabbi M; Brizzolara A; Lanza F; Mosci C; Salvi S; Gualco M; Truini M; Angelini G; Boccardo S; Cilli M; Airoldi I; Queirolo P; Jager MJ; Daga A; Pfeffer U; Ferrini S
    PLoS One; 2012; 7(1):e29989. PubMed ID: 22267972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.
    Stutz E; Gautschi O; Fey MF; Gugger M; Tschan MP; Rothschild SI
    Future Oncol; 2014 Feb; 10(2):211-7. PubMed ID: 24490607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
    Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
    Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.
    Dong F; Lou D
    Mol Vis; 2012; 18():537-46. PubMed ID: 22419847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
    Wang Y; Liu M; Jin Y; Jiang S; Pan J
    Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.